Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
01.05.2011 | Präsentationstitel von Dr. Vorname Nachname 12014 | RIEMSER Pharma GmbH
RIEMSER Pharma GmbH
Ready for the Future
Jefferies Health Care Conference
19th & 20th November 2014
The Waldorf Hilton, London
22014 | RIEMSER Pharma GmbH
Excellence in Marketing and Sales
Strong Market Access and Regulatory experience
Highly efficient BD team
Well-established international partner
network
Fast international market access
Strong marketing capabilities
32014 | RIEMSER Pharma GmbH
■ With RIEMSER since April
2011
■ Previously worked for MARS,
BRITA Waterfilters, Teraklin
and Vaillant
Corporate Structure
Kai Deusch, M.D. PhDChief Executive Officer
Beatrice von BuchwaldtChief Financial Officer
■ RIEMSER supervisory board since
Sept. 2012, CEO since Feb. 2014
■ Senior positions in
■ Clinical Academia (Harvard DFCI,
University Munich)
■ Consulting: McKinsey & Company
■ Private Equity: Director, Apax
Partners, Medicis
■ Various pharma & medtech
companies
Advisory BoardElmar Stachels PhD (formerly Bayer)
Thomas Werner PhD (formerly MD GSK,
BMS- Germany)
Burkhart Blank MD (formerly Boehringer I)
Christophe PasikManaging Director Keocyt
(formerly Pfizer France)
EU5-CountryManaging Director
EU5-CountryManaging Director
42014 | RIEMSER Pharma GmbH
Phase 1
1991-2008
Phase 2
2009-2012
Phase 3
2012 to date
Strategic Metamorphosis
Divestment of RIEMSER‘s non-
strategic business:
o Dental ORM /OIM
o Manufacturing sites
o Reduction of portfolio by 50% to
approx. 50 products
Geographic (EU) Footprinting
& Strategic Portfolio
Expansion
o Acquisition of Keocyt in
France (04/2014) with 2
Oncology and 2 Neurology
products + pipeline
o Acquisition plans in Italy,
Spain and UK
o Strategic product/portfolio
acquisitions
Consolidation & Strategic Growth
Strategic focus on oncology, anti-
infectives and dermatology
Targeted acquisitions and
developments (Aloxi, Ostac,Tepadina)
and divestments (animal health)
Initiation of internationalization
Diversified Pharma / Device /
OTC Company
Merger of RIEMSER
Tierarzneimittel (animal health)
with Palmicol into RIEMSER
Arzneimittel GmbH
Acquisition of dental business
and 400+ marketing
authorisations
Dynamic Development Acquisition by
Ardian Private Equity
52014 | RIEMSER Pharma GmbH
Continuous Growth
Sales close to € 110m in 2014CAGR (%)
9.2%
13.9%
6.7%
68%
71% 68% 61% 62%
32%
29%
32%
39% 38%
2009 2010 2011 2012 2013
National International
62014 | RIEMSER Pharma GmbH
Re-launch and repositioning of
existing products
Launch of innovative niche products
and orphan drugs
Acquisition and integration
capabilities
Licensing of strategic products
Core Competencies
Anti-infectives 22%
Dermatology 8%
Oncology 30%
Cardiovascular15%
Others 25%(e.g. Immunology/
Obesity)
Global distribution network
72014 | RIEMSER Pharma GmbH
Key Therapeutic Areas
Tepadina
Aloxi
Ostac
Gelclair
Zanosar
Estracyt
Akynzeo*
Dedicated sales
force in Germany
and France
Dilantin
Prodilantin
Dedicated sales
force in France
Vancomycin
Enterocaps
Eremfat
KOL network
Direct Marketing
Cardiovascular
Vagantin
Bite-away
Herpotherm
KOL network
Direct Marketing
Lanitop
Ismo
Aldactone
KOL network
Direct Marketing
*pre-approval phase
DermatologyAnti-InfectivesNeurologyOncology
82014 | RIEMSER Pharma GmbH
RIEMSER Can Make a Difference (1)
Aloxi
5-HT3 receptor antagonist
for prevention of CT-
induced nausea and
vomiting
Launched in 2005
In-licensed from Helsinn in
2008 after flattened sales
development by previous
licensee
Re-positioning as “best-in-
class” setron
0
1,000,000
2,000,000
3,000,000
4,000,000
5,000,000
6,000,000
7,000,000
8,000,000
2007 2009 2013
+112%*
+484%
*First full year with RIEMSER versus last full year with previous licensee
Retail Sales (€)
92014 | RIEMSER Pharma GmbH
RIEMSER Can Make a Difference (2)
Tepadina
For conditioning treatment
prior to HSCT
Developed in a global
partnership with Adienne
New MA granted in 3/2010
New positioning with
orphan drug status at an
attractive price
Expansion into new
indications and markets
(France, selected Eastern
European countries, Asia)
*First year after repositioning versus previous year
0
1,000,000
2,000,000
3,000,000
4,000,000
5,000,000
6,000,000
7,000,000
8,000,000
9,000,000
10,000,000
2009 2010 2013
+171%*
+557%Sales (€)
102014 | RIEMSER Pharma GmbH
RIEMSER Can Make a Difference (3)
Bite-away
Electrical device to treat
insect bites
Initiation of direct-to-customer
promotion in 2013
Usage by celebrities
Distribution through Amazon
etc.
Line extension for the
treatment of herpes labialis
*First year after start of DTC promotion versus previous year
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
1,400,000
1,600,000
1,800,000
2012 2013
+170%*
Sales (€)
112014 | RIEMSER Pharma GmbH
Mission & Strategy
Mission
Establish a leading European
specialty pharma player
o Marketing & distribution
excellence in complex disease
areas
o Efficient BD transaction team
o Proprietary deal flow through
unique network
o Ideal partner for innovative
companies to launch specialty
products in Europe
Strategy
Focus on therapeutics and supportive
care products around selected
complex disease areas
Employ/grow expert market access &
distribution know how
Establish solid footprint in key
European regions through targeted
acquisitions
122014 | RIEMSER Pharma GmbH
Becoming an European Specialty Pharma Player
Riemser France
Riemser Europe
Transition towards a fully integrated European company
132014 | RIEMSER Pharma GmbH
Worldwide Distribution Network with Trusted Partners
SP = specialty pharma products, EP= established pharma products
142014 | RIEMSER Pharma GmbH
Key Priorities for the Future
Focus on Key
Therapeutic Areas
Continue Acquisition
and Licensing Strategy
Expand European
Footprint
• Build on existing expertise in Oncology,
Dermatology, Anti-infectives and
Cardiovascular
• Use existing competencies to tap into
Autoimmune diseases, Immunology,
Neurology and Transplantation
• Experienced and flexible team
• Efficient and effective execution
• Establish affiliates in all Big 5 countries
• Become an European specialty pharma player
with an entrepreneurial spirit
• Manage and expand current well- functioning
partner network
152014 | RIEMSER Pharma GmbH
RIEMSER is your preferred partner for:
Company Acquisitions
Product Acquisition
LicensingCo-
promotion
Co-detailing
162014 | RIEMSER Pharma GmbH
Highly focused specialty pharma company ideally suited to serve as partner for innovative
pharma companies targeting disease areas with high unmet medical need
Rich global pipelines in oncology, immunology and other complex/niche chronic diseases
require highly specialized partners such as RIEMSER
Rise of personalized medicine requires more refined sales strategies than in the past
RIEMSER is perfectly positioned to market innovative, non-mainstream
therapeutics in oncology, autoimmunity, neurology and other specialty niches
RIEMSER Pharma
In Summary
172014 | RIEMSER Pharma GmbH
THANK YOU